February 21, 2021The LancetOpen Access

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

View Full Paper

Ask AI

Bookmark

Abstract

UK Research and Innovation, National Institutes of Health Research (NIHR), The Coalition for Epidemic Preparedness Innovations, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D'Or, the Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Voysey et al. (2021) studied this question.

synapsesocial.com/papers/69d8100aba18484428d185f7 https://doi.org/10.1016/s0140-6736(21)00432-3

View Full Paper

Ask AI

Bookmark

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Abstract

Discussion

Cite This Study

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Abstract

Discussion

Cite This Study

Also Consider

Also Consider